GlassScriptPhysician profile
Jeanette Keith
NPI 1124180674
$2,535.16
in general payments reported to CMS, 2019-2025
14 companies · $168 in 2025
The $168 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $11.56 · 2021: $202 · 2022: $147 · 2023: $473 · 2024: $1,429 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,210 · Travel and Lodging: $778 · Gift: $81.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,210.38 |
| Travel and Lodging | $778.29 |
| Gift | $81.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Enterra Medical, INC. | $1,315.79 | 2023-2024 | |
| Abbvie INC. | $383.12 | 2019-2025 | |
| Ardelyx, INC. | $216.21 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $174.28 | 2021-2024 | Entyvio |
| Evoke Pharma, INC. | $97.15 | 2022-2024 | Gimoti |
| Braintree Laboratories, INC. | $93.37 | 2020-2023 | Sutab |
| E.R. Squibb & Sons, L.L.C. | $61.53 | 2023 | |
| Merck Sharp & Dohme LLC | $54.22 | 2019-2024 | Dificid |
| Pfizer INC. | $42.76 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.27 | 2019 | |
| Gilead Sciences, INC. | $19.47 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $17.56 | 2022 | |
| Phathom Pharmaceuticals, INC. | $17.35 | 2024 | Voquezna |
| Lilly USA, LLC | $13.08 | 2024 | Omvoh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeanette Keith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.